# Safety of Cetuximab and Trifluridin Tipiracil as the Third-line Therapy in the RASwt mCRC

> **NCT05155124** · PHASE1 · UNKNOWN · sponsor: **Union Hospital, Tongji Medical College, Huazhong University of Science and Technology** · enrollment: 6 (estimated)

## Conditions studied

- Colorectal Neoplasms Malignant

## Interventions

- **DRUG:** Cetuximab + trifluridin tipiracil

## Key facts

- **NCT ID:** NCT05155124
- **Lead sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09
- **Primary completion:** 2022-10
- **Final completion:** 2023-04
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2022-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05155124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05155124, "Safety of Cetuximab and Trifluridin Tipiracil as the Third-line Therapy in the RASwt mCRC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05155124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*